{"content_html": "<p id=\"speakable-summary\">This morning, a publicly traded transplant diagnostics company called <a href=\"https://www.caredxinc.com/\">CareDx</a>, along with Stanford University, sued another publicly traded genetic testing company, <a href=\"https://www.natera.com/\">Natera</a>, for patent infringement.</p> <p>Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks poised to play center stage again in future corporate battles.</p> <p>Loosely defined, cell-free DNA (or cfDNA) technology involves blood tests that enable physicians to understand what\u2019s happening in someone\u2019s body. They\u2019re not looking at red or white blood cells (thus the \u201ccell free\u201d part) but at plasma, which carries pieces of broken-up DNA, among other things.</p> <p>Companies like <a href=\"https://www.investors.com/news/technology/guardant-health-ipo/\">newly</a> public <a href=\"https://guardanthealth.com/\">Guardant Health</a> are using it to try to ensure that cancer patients receive the right drugs. Prenatal cfDNA screening has meanwhile become a common way to screen for specific chromosomal problems in a developing baby \u2014 including Down syndrome, trisomy 13 and trisomy 18. The latter has become particularly popular as an alternative to amniocentesis, a more intrusive, and sometimes high-risk, procedure in which a small amount of amniotic fluid is sampled from the amniotic sac surrounding a developing fetus.</p> <p>Yet another way that cfDNA testing can monitor clinical conditions and make a major impact on healthcare is by distinguishing the relative proportion of DNA molecules in a patient\u2019s blood after that person has had an organ transplant. Though traditionally, recipients have had to undergo biopsies to gauge whether or not their new organ was being accepted or rejected, it\u2019s now possible to measure through the far-less traumatic process of providing blood samples. (Broadly speaking, if, over time, the amount of donor DNA increases in the patient\u2019s blood, things aren\u2019t going well.)</p> <p>It\u2019s an important, if relatively new, development, and CareDx, a 19-year-old, Brisbane, Calif.-based company that went public in 2014, claims in its newly filed lawsuit that two patents it controls give it the exclusive right to non-invasively diagnose graft rejection in a great many organ transplant patients via cfDNA testing. What we mean: <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=9845497.PN.&amp;OS=PN/9845497&amp;RS=PN/9845497\">one of the patents</a> covers \u201ckidney transplant, a heart transplant, a liver transplant, a pancreas transplant, a lung transplant, a skin transplant, and any combination thereof.\u201d The <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=8703652.PN.&amp;OS=PN/8703652&amp;RS=PN/8703652\">second patent</a> covers 16 different methods, devices, compositions and kits for diagnosing or predicting transplant status or patient outcome.</p> <p>The patents were awarded in recent years to Stanford academics, including Stephen Quake, a renowned professor of bioengineering and applied physics. Though Stanford owns the patents, however, it licenses them to CareDx, and they\u2019ve dramatically enhanced the company\u2019s prospects. Indeed, while its shares were priced at $10 apiece at the time of its IPO, they\u2019ve been trading at $40 each more recently, thanks largely to its <a href=\"http://www.allosure.com/\">AlloSure</a> test, which is designed specifically for kidney transplant patients and, critically, is now covered by Medicare.</p> <p>Indeed, CareDx\u2019s lawsuit against 15-year-old <a class=\"crunchbase-link\" data-entity=\"natera\" data-type=\"organization\" href=\"https://crunchbase.com/organization/natera\" target=\"_blank\">Natera, <span class=\"crunchbase-tooltip-indicator\"></span></a> which went public in 2015, accuses it of \u201cpreparing to develop and commercialize\u201d a too-similar kidney transplant rejection test beginning in the middle of last year. It\u2019s seeking cash compensation and a court order that blocks the sale of Natera\u2019s offering.</p> <p>It\u2019s an offensive move, too, seemingly, given all those other organs at stake and the markets they could unlock.</p> <p>Natera, which counts <a class=\"crunchbase-link\" data-entity=\"sequoia-capital\" data-type=\"organization\" href=\"https://crunchbase.com/organization/sequoia-capital\" target=\"_blank\">Sequoia Capital\u2019s <span class=\"crunchbase-tooltip-indicator\"></span></a> Roelof Botha as a board member, did not provide an executive to comment on the suit. Botha also declined through a Sequoia spokesperson to comment. But Natera told us in a statement that it\u2019s \u201cconfident that we will prevail in this suit should it proceed and do not expect this suit to impact our commercialization plans or disrupt our operations in any way.\u201d Added the company, \u201cWe are not surprised that CareDx would attempt to disrupt the imminent commercialization of Natera\u2019s innovative organ transplant rejection test, which does not require donor genotyping, and will compete with CareDx\u2019s older test. In recently published studies, Natera demonstrated superior analytical and clinical test performance.\u201d</p> <p>What happens next remains to be seen, but it\u2019s not the first imbroglio in which Natera finds itself.\u00a0 A year ago, the gene-testing company <a class=\"crunchbase-link\" data-entity=\"illumina\" data-type=\"organization\" href=\"https://crunchbase.com/organization/illumina\" target=\"_blank\">Illumina <span class=\"crunchbase-tooltip-indicator\"></span></a> filed a lawsuit against Natera, alleging that the company\u2019s non-invasive prenatal testing infringes a patent that Illumina controls and that relies on analysis of cell-free DNA present in maternal blood. That case is still <a href=\"https://ecf.cand.uscourts.gov/doc1/035117771847\">moving toward a trial</a>. In the meantime, Illumina last year separately won a <a href=\"https://www.sdbj.com/news/2018/jan/29/illumina-awarded-267-million-patent-infringement-l/\">$26.7 million jury verdict</a> in a lawsuit accusing a subsidiary of Roche Holdings of using patented prenatal testing technology without authorization.</p> <p>Last year, Natera also agreed to pay <a href=\"https://www.genomeweb.com/molecular-diagnostics/natera-settles-billing-lawsuit-us-government-114m#.XJpsaetKiL8\">$11.4 million</a> to settle a lawsuit with the U.S. government, after it alleged that Natera submitted false claims to several government health programs based on tips by two former Natera employees who filed an earlier whistleblower lawsuit against the company.</p> <p>Natera \u2014 whose founding CEO, Matthew Rabinowitz, stepped down from his position in January of this year, replaced by longtime Natera employee and COO Steve Chapman \u2014 denied the allegations and, as part of the settlement terms, did not admit any wrongdoing.</p> <p>Either way, Natera, CareDx and Illumina aren\u2019t the only ones duking it out over cell-free DNA testing.</p> <p>In 2017, for example, Guardant <a href=\"https://www.genomeweb.com/business-news/guardant-health-sues-foundation-medicine-false-advertising#.XJp2TOtKiL8\">filed a lawsuit</a> against rival Foundation Medicine, alleging that Foundation\u2019s advertising for its own liquid and tissue tests harmed both Guardant and cancer patients by misleading oncologists about the relative accuracy and sensitivity of the competing genomic tests. Foundation later <a href=\"https://www.genomeweb.com/cancer/foundation-medicine-sues-guardant-health-patent-infringement\" rel=\"noopener noreferrer\" target=\"_blank\">sued Guardant</a>, alleging infringement of a patent that covers methods for analyzing a cancer patient\u2019s tissue or blood sample to detect multiple classes of genomic alterations.</p> <p>The two companies <a href=\"http://investors.foundationmedicine.com/news-releases/news-release-details/foundation-medicine-and-guardant-health-agree-settle-patent\">later settled</a> both without disclosing the terms of their agreement, but Guardant has more recently <a href=\"https://www.pacermonitor.com/public/case/22954496/Guardant_Health,_Inc_v_Foundation_Medicine,_Inc\">sued Foundation again</a>. It is also embroiled in an <a href=\"https://insight.rpxcorp.com/litigation_documents/12851668\">ongoing lawsuit</a> against another rival called Personal Genome Diagnostics over its cell-free DNA technology.</p> ", "content": "This morning, a publicly traded transplant diagnostics company called  CareDx  , along with Stanford University, sued another publicly traded genetic testing company,  Natera  , for patent infringement.  Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks poised to play center stage again in future corporate battles.  Loosely defined, cell-free DNA (or cfDNA) technology involves blood tests that enable physicians to understand what\u2019s happening in someone\u2019s body. They\u2019re not looking at red or white blood cells (thus the \u201ccell free\u201d part) but at plasma, which carries pieces of broken-up DNA, among other things.  Companies like  newly   public  Guardant Health   are using it to try to ensure that cancer patients receive the right drugs. Prenatal cfDNA screening has meanwhile become a common way to screen for specific chromosomal problems in a developing baby \u2014 including Down syndrome, trisomy 13 and trisomy 18. The latter has become particularly popular as an alternative to amniocentesis, a more intrusive, and sometimes high-risk, procedure in which a small amount of amniotic fluid is sampled from the amniotic sac surrounding a developing fetus.  Yet another way that cfDNA testing can monitor clinical conditions and make a major impact on healthcare is by distinguishing the relative proportion of DNA molecules in a patient\u2019s blood after that person has had an organ transplant. Though traditionally, recipients have had to undergo biopsies to gauge whether or not their new organ was being accepted or rejected, it\u2019s now possible to measure through the far-less traumatic process of providing blood samples. (Broadly speaking, if, over time, the amount of donor DNA increases in the patient\u2019s blood, things aren\u2019t going well.)  It\u2019s an important, if relatively new, development, and CareDx, a 19-year-old, Brisbane, Calif.-based company that went public in 2014, claims in its newly filed lawsuit that two patents it controls give it the exclusive right to non-invasively diagnose graft rejection in a great many organ transplant patients via cfDNA testing. What we mean:  one of the patents   covers \u201ckidney transplant, a heart transplant, a liver transplant, a pancreas transplant, a lung transplant, a skin transplant, and any combination thereof.\u201d The  second patent   covers 16 different methods, devices, compositions and kits for diagnosing or predicting transplant status or patient outcome.  The patents were awarded in recent years to Stanford academics, including Stephen Quake, a renowned professor of bioengineering and applied physics. Though Stanford owns the patents, however, it licenses them to CareDx, and they\u2019ve dramatically enhanced the company\u2019s prospects. Indeed, while its shares were priced at $10 apiece at the time of its IPO, they\u2019ve been trading at $40 each more recently, thanks largely to its  AlloSure   test, which is designed specifically for kidney transplant patients and, critically, is now covered by Medicare.  Indeed, CareDx\u2019s lawsuit against 15-year-old  Natera,     which went public in 2015, accuses it of \u201cpreparing to develop and commercialize\u201d a too-similar kidney transplant rejection test beginning in the middle of last year. It\u2019s seeking cash compensation and a court order that blocks the sale of Natera\u2019s offering.  It\u2019s an offensive move, too, seemingly, given all those other organs at stake and the markets they could unlock.  Natera, which counts  Sequoia Capital\u2019s     Roelof Botha as a board member, did not provide an executive to comment on the suit. Botha also declined through a Sequoia spokesperson to comment. But Natera told us in a statement that it\u2019s \u201cconfident that we will prevail in this suit should it proceed and do not expect this suit to impact our commercialization plans or disrupt our operations in any way.\u201d Added the company, \u201cWe are not surprised that CareDx would attempt to disrupt the imminent commercialization of Natera\u2019s innovative organ transplant rejection test, which does not require donor genotyping, and will compete with CareDx\u2019s older test. In recently published studies, Natera demonstrated superior analytical and clinical test performance.\u201d  What happens next remains to be seen, but it\u2019s not the first imbroglio in which Natera finds itself.\u00a0 A year ago, the gene-testing company  Illumina     filed a lawsuit against Natera, alleging that the company\u2019s non-invasive prenatal testing infringes a patent that Illumina controls and that relies on analysis of cell-free DNA present in maternal blood. That case is still  moving toward a trial  . In the meantime, Illumina last year separately won a  $26.7 million jury verdict   in a lawsuit accusing a subsidiary of Roche Holdings of using patented prenatal testing technology without authorization.  Last year, Natera also agreed to pay  $11.4 million   to settle a lawsuit with the U.S. government, after it alleged that Natera submitted false claims to several government health programs based on tips by two former Natera employees who filed an earlier whistleblower lawsuit against the company.  Natera \u2014 whose founding CEO, Matthew Rabinowitz, stepped down from his position in January of this year, replaced by longtime Natera employee and COO Steve Chapman \u2014 denied the allegations and, as part of the settlement terms, did not admit any wrongdoing.  Either way, Natera, CareDx and Illumina aren\u2019t the only ones duking it out over cell-free DNA testing.  In 2017, for example, Guardant  filed a lawsuit   against rival Foundation Medicine, alleging that Foundation\u2019s advertising for its own liquid and tissue tests harmed both Guardant and cancer patients by misleading oncologists about the relative accuracy and sensitivity of the competing genomic tests. Foundation later  sued Guardant  , alleging infringement of a patent that covers methods for analyzing a cancer patient\u2019s tissue or blood sample to detect multiple classes of genomic alterations.  The two companies  later settled   both without disclosing the terms of their agreement, but Guardant has more recently  sued Foundation again  . It is also embroiled in an  ongoing lawsuit   against another rival called Personal Genome Diagnostics over its cell-free DNA technology.  ", "title_html": "<h1 class=\"article__title\">A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing</h1> ", "url": "https://techcrunch.com/2019/03/26/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing", "title": "A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing  ", "html": "<!DOCTYPE html>\n\n<html class=\"no-js\" lang=\"en-US\">\n<head>\n<meta charset=\"utf-8\"/>\n<meta content=\"IE=Edge\" http-equiv=\"X-UA-Compatible\"><script type=\"text/javascript\">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o||n)},o,o.exports)}return n[t].exports}if(\"function\"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({1:[function(e,n,t){function r(){}function o(e,n,t){return function(){return i(e,[c.now()].concat(u(arguments)),n?null:this,t),n?void 0:this}}var i=e(\"handle\"),a=e(3),u=e(4),f=e(\"ee\").get(\"tracer\"),c=e(\"loader\"),s=NREUM;\"undefined\"==typeof window.newrelic&&(newrelic=s);var p=[\"setPageViewName\",\"setCustomAttribute\",\"setErrorHandler\",\"finished\",\"addToTrace\",\"inlineHit\",\"addRelease\"],d=\"api-\",l=d+\"ixn-\";a(p,function(e,n){s[n]=o(d+n,!0,\"api\")}),s.addPageAction=o(d+\"addPageAction\",!0),s.setCurrentRouteName=o(d+\"routeName\",!0),n.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(e,n){var t={},r=this,o=\"function\"==typeof n;return i(l+\"tracer\",[c.now(),e,t],r),function(){if(f.emit((o?\"\":\"no-\")+\"fn-start\",[c.now(),r,o],t),o)try{return n.apply(this,arguments)}catch(e){throw f.emit(\"fn-err\",[arguments,this,e],t),e}finally{f.emit(\"fn-end\",[c.now()],t)}}}};a(\"actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get\".split(\",\"),function(e,n){m[n]=o(l+n)}),newrelic.noticeError=function(e,n){\"string\"==typeof e&&(e=new Error(e)),i(\"err\",[e,c.now(),!1,n])}},{}],2:[function(e,n,t){function r(e,n){if(!o)return!1;if(e!==o)return!1;if(!n)return!0;if(!i)return!1;for(var t=i.split(\".\"),r=n.split(\".\"),a=0;a<r.length;a++)if(r[a]!==t[a])return!1;return!0}var o=null,i=null,a=/Version\\/(\\S+)\\s+Safari/;if(navigator.userAgent){var u=navigator.userAgent,f=u.match(a);f&&u.indexOf(\"Chrome\")===-1&&u.indexOf(\"Chromium\")===-1&&(o=\"Safari\",i=f[1])}n.exports={agent:o,version:i,match:r}},{}],3:[function(e,n,t){function r(e,n){var t=[],r=\"\",i=0;for(r in e)o.call(e,r)&&(t[i]=n(r,e[r]),i+=1);return t}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],4:[function(e,n,t){function r(e,n,t){n||(n=0),\"undefined\"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(o<0?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=r},{}],5:[function(e,n,t){n.exports={exists:\"undefined\"!=typeof window.performance&&window.performance.timing&&\"undefined\"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(e,n,t){function r(){}function o(e){function n(e){return e&&e instanceof r?e:e?f(e,u,i):i()}function t(t,r,o,i){if(!d.aborted||i){e&&e(t,r,o);for(var a=n(o),u=v(t),f=u.length,c=0;c<f;c++)u[c].apply(a,r);var p=s[y[t]];return p&&p.push([b,t,r,a]),a}}function l(e,n){h[e]=v(e).concat(n)}function m(e,n){var t=h[e];if(t)for(var r=0;r<t.length;r++)t[r]===n&&t.splice(r,1)}function v(e){return h[e]||[]}function g(e){return p[e]=p[e]||o(t)}function w(e,n){c(e,function(e,t){n=n||\"feature\",y[t]=n,n in s||(s[n]=[])})}var h={},y={},b={on:l,addEventListener:l,removeEventListener:m,emit:t,get:g,listeners:v,context:n,buffer:w,abort:a,aborted:!1};return b}function i(){return new r}function a(){(s.api||s.feature)&&(d.aborted=!0,s=d.backlog={})}var u=\"nr@context\",f=e(\"gos\"),c=e(3),s={},p={},d=n.exports=o();d.backlog=s},{}],gos:[function(e,n,t){function r(e,n,t){if(o.call(e,n))return e[n];var r=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return e[n]=r,r}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],handle:[function(e,n,t){function r(e,n,t,r){o.buffer([e],r),o.emit(e,n,t)}var o=e(\"ee\").get(\"handle\");n.exports=r,r.ee=o},{}],id:[function(e,n,t){function r(e){var n=typeof e;return!e||\"object\"!==n&&\"function\"!==n?-1:e===window?0:a(e,i,function(){return o++})}var o=1,i=\"nr@id\",a=e(\"gos\");n.exports=r},{}],loader:[function(e,n,t){function r(){if(!E++){var e=x.info=NREUM.info,n=l.getElementsByTagName(\"script\")[0];if(setTimeout(s.abort,3e4),!(e&&e.licenseKey&&e.applicationID&&n))return s.abort();c(y,function(n,t){e[n]||(e[n]=t)}),f(\"mark\",[\"onload\",a()+x.offset],null,\"api\");var t=l.createElement(\"script\");t.src=\"https://\"+e.agent,n.parentNode.insertBefore(t,n)}}function o(){\"complete\"===l.readyState&&i()}function i(){f(\"mark\",[\"domContent\",a()+x.offset],null,\"api\")}function a(){return O.exists&&performance.now?Math.round(performance.now()):(u=Math.max((new Date).getTime(),u))-x.offset}var u=(new Date).getTime(),f=e(\"handle\"),c=e(3),s=e(\"ee\"),p=e(2),d=window,l=d.document,m=\"addEventListener\",v=\"attachEvent\",g=d.XMLHttpRequest,w=g&&g.prototype;NREUM.o={ST:setTimeout,SI:d.setImmediate,CT:clearTimeout,XHR:g,REQ:d.Request,EV:d.Event,PR:d.Promise,MO:d.MutationObserver};var h=\"\"+location,y={beacon:\"bam.nr-data.net\",errorBeacon:\"bam.nr-data.net\",agent:\"js-agent.newrelic.com/nr-1118.min.js\"},b=g&&w&&w[m]&&!/CriOS/.test(navigator.userAgent),x=n.exports={offset:u,now:a,origin:h,features:{},xhrWrappable:b,userAgent:p};e(1),l[m]?(l[m](\"DOMContentLoaded\",i,!1),d[m](\"load\",r,!1)):(l[v](\"onreadystatechange\",o),d[v](\"onload\",r)),f(\"mark\",[\"firstbyte\",u],null,\"api\");var E=0,O=e(5)},{}]},{},[\"loader\"]);</script>\n<meta content=\"width=device-width\" name=\"viewport\"/>\n<meta content=\"initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0\" name=\"viewport\"/>\n<link href=\"http://gmpg.org/xfn/11\" rel=\"profile\"/>\n<link href=\"https://techcrunch.com/xmlrpc.php\" rel=\"pingback\"/>\n<title>A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing \u2013 TechCrunch</title>\n<link href=\"//consent.cmp.oath.com\" rel=\"dns-prefetch\">\n<link href=\"//s.yimg.com\" rel=\"dns-prefetch\">\n<link href=\"//use.typekit.net\" rel=\"dns-prefetch\"/>\n<link href=\"//cdn.vidible.tv\" rel=\"dns-prefetch\"/>\n<link href=\"//plugin.mediavoice.com\" rel=\"dns-prefetch\"/>\n<link href=\"//s.w.org\" rel=\"dns-prefetch\"/>\n<link href=\"https://techcrunch.com/feed/\" rel=\"alternate\" title=\"TechCrunch \u00bb Feed\" type=\"application/rss+xml\"/>\n<link href=\"https://techcrunch.com/comments/feed/\" rel=\"alternate\" title=\"TechCrunch \u00bb Comments Feed\" type=\"application/rss+xml\"/>\n<link href=\"https://techcrunch.com/2019/03/26/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing/feed/\" rel=\"alternate\" title=\"TechCrunch \u00bb A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing Comments Feed\" type=\"application/rss+xml\"/>\n<meta content=\"false\" name=\"oath:guce:product-eu\">\n<meta content=\"guce.techcrunch.com\" name=\"oath:guce:consent-host\">\n<meta content=\"true\" name=\"oath:guce:inline-consent\"/>\n<script async=\"\" src=\"//s.yimg.com/oa/guce.js?tc_ver=190405\"></script>\n<script type=\"text/javascript\">\n\t\t\twindow._wpemojiSettings = {\"baseUrl\":\"https:\\/\\/s.w.org\\/images\\/core\\/emoji\\/11.2.0\\/72x72\\/\",\"ext\":\".png\",\"svgUrl\":\"https:\\/\\/s.w.org\\/images\\/core\\/emoji\\/11.2.0\\/svg\\/\",\"svgExt\":\".svg\",\"source\":{\"concatemoji\":\"https:\\/\\/techcrunch.com\\/wp-includes\\/js\\/wp-emoji-release.min.js?ver=5.1.1\"}};\n\t\t\t!function(a,b,c){function d(a,b){var c=String.fromCharCode;l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,a),0,0);var d=k.toDataURL();l.clearRect(0,0,k.width,k.height),l.fillText(c.apply(this,b),0,0);var e=k.toDataURL();return d===e}function e(a){var b;if(!l||!l.fillText)return!1;switch(l.textBaseline=\"top\",l.font=\"600 32px Arial\",a){case\"flag\":return!(b=d([55356,56826,55356,56819],[55356,56826,8203,55356,56819]))&&(b=d([55356,57332,56128,56423,56128,56418,56128,56421,56128,56430,56128,56423,56128,56447],[55356,57332,8203,56128,56423,8203,56128,56418,8203,56128,56421,8203,56128,56430,8203,56128,56423,8203,56128,56447]),!b);case\"emoji\":return b=d([55358,56760,9792,65039],[55358,56760,8203,9792,65039]),!b}return!1}function f(a){var c=b.createElement(\"script\");c.src=a,c.defer=c.type=\"text/javascript\",b.getElementsByTagName(\"head\")[0].appendChild(c)}var g,h,i,j,k=b.createElement(\"canvas\"),l=k.getContext&&k.getContext(\"2d\");for(j=Array(\"flag\",\"emoji\"),c.supports={everything:!0,everythingExceptFlag:!0},i=0;i<j.length;i++)c.supports[j[i]]=e(j[i]),c.supports.everything=c.supports.everything&&c.supports[j[i]],\"flag\"!==j[i]&&(c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&c.supports[j[i]]);c.supports.everythingExceptFlag=c.supports.everythingExceptFlag&&!c.supports.flag,c.DOMReady=!1,c.readyCallback=function(){c.DOMReady=!0},c.supports.everything||(h=function(){c.readyCallback()},b.addEventListener?(b.addEventListener(\"DOMContentLoaded\",h,!1),a.addEventListener(\"load\",h,!1)):(a.attachEvent(\"onload\",h),b.attachEvent(\"onreadystatechange\",function(){\"complete\"===b.readyState&&c.readyCallback()})),g=c.source||{},g.concatemoji?f(g.concatemoji):g.wpemoji&&g.twemoji&&(f(g.twemoji),f(g.wpemoji)))}(window,document,window._wpemojiSettings);\n\t\t</script>\n<style type=\"text/css\">\nimg.wp-smiley,\nimg.emoji {\n\tdisplay: inline !important;\n\tborder: none !important;\n\tbox-shadow: none !important;\n\theight: 1em !important;\n\twidth: 1em !important;\n\tmargin: 0 .07em !important;\n\tvertical-align: -0.1em !important;\n\tbackground: none !important;\n\tpadding: 0 !important;\n}\n</style>\n<link href=\"https://techcrunch.com/_static/??/wp-includes/css/dist/block-library/style.min.css,/wp-content/plugins/wp-parsely/wp-parsely.css,/wp-content/themes/techcrunch-2017/build/ec/css/main.css?m=1554501095\" id=\"all-css-0\" media=\"all\" rel=\"stylesheet\" type=\"text/css\"/>\n<script src=\"https://consent.cmp.oath.com/cmp.js?ver=5.1.1\" type=\"text/javascript\"></script>\n<script src=\"https://techcrunch.com/_static/??-eJzTLy/QzcxLzilNSS3WzwKiwtLUokoopZdVrKOPT4FubmZ6UWJJql5uZh5QsX2uraGpqZGJiZGhsUUWACVfIKk=\" type=\"text/javascript\"></script>\n<script src=\"https://s.yimg.com/ss/rapid3.js?ver=5.1.1\" type=\"text/javascript\"></script>\n<script src=\"//cdn.vidible.tv/prod/player/js/latest/vidible-min.js?ver=5.1.1\" type=\"text/javascript\"></script>\n<script src=\"//plugin.mediavoice.com/mediaconductor/mc.js?ver=5.1.1\" type=\"text/javascript\"></script>\n<link href=\"https://techcrunch.com/wp-json/\" rel=\"https://api.w.org/\"/>\n<link href=\"https://techcrunch.com/xmlrpc.php?rsd\" rel=\"EditURI\" title=\"RSD\" type=\"application/rsd+xml\"/>\n<link href=\"https://techcrunch.com/wp-includes/wlwmanifest.xml\" rel=\"wlwmanifest\" type=\"application/wlwmanifest+xml\"/>\n<meta content=\"WordPress 5.1.1\" name=\"generator\"/>\n<link href=\"https://techcrunch.com/2019/03/26/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing/\" rel=\"canonical\"/>\n<link href=\"https://techcrunch.com/?p=1801038\" rel=\"shortlink\"/>\n<link href=\"https://techcrunch.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftechcrunch.com%2F2019%2F03%2F26%2Fa-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing%2F\" rel=\"alternate\" type=\"application/json+oembed\"/>\n<link href=\"https://techcrunch.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Ftechcrunch.com%2F2019%2F03%2F26%2Fa-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing%2F&amp;format=xml\" rel=\"alternate\" type=\"text/xml+oembed\"/>\n<link href=\"//v0.wordpress.com\" rel=\"dns-prefetch\"/>\n<style type=\"text/css\">img#wpstats{display:none}</style>\n<!-- BEGIN Sailthru Horizon Meta Information -->\n<meta content=\"2019-03-26 14:36:29\" name=\"sailthru.date\"/>\n<meta content=\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing\" name=\"sailthru.title\"/>\n<meta content=\"CareDx, guardant health, Illumina, Natera, sequoia capital, Stanford University\" name=\"sailthru.tags\"/>\n<meta content=\"This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement.\" name=\"sailthru.description\"/>\n<meta content=\"https://techcrunch.com/wp-content/uploads/2016/03/boxing-gloves-businessman.jpg\" name=\"sailthru.image.full\"/>\n<meta content=\"https://techcrunch.com/wp-content/uploads/2016/03/boxing-gloves-businessman.jpg?w=50\" name=\"sailthru.image.thumb\"/>\n<!-- END Sailthru Horizon Meta Information -->\n<!-- BEGIN wp-parsely Plugin Version 1.13.0 -->\n<meta content=\"1.13.0\" id=\"wp-parsely_version\" name=\"wp-parsely_version\"/>\n<script type=\"application/ld+json\">\n\t{\"@context\":\"http:\\/\\/schema.org\",\"@type\":\"NewsArticle\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"http:\\/\\/techcrunch.com\\/2019\\/03\\/26\\/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\\/\"},\"headline\":\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing\",\"url\":\"http:\\/\\/techcrunch.com\\/2019\\/03\\/26\\/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\\/\",\"thumbnailUrl\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=150\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=150\"},\"dateCreated\":\"2019-03-26T21:36:29Z\",\"datePublished\":\"2019-03-26T21:36:29Z\",\"dateModified\":\"2019-03-26T21:36:29Z\",\"articleSection\":\"post\",\"author\":[{\"@type\":\"Person\",\"name\":\"Connie Loizos\"}],\"creator\":[\"Connie Loizos\"],\"keywords\":[\"@post-id:1801038\",\"health\",\"lawsuit\",\"tc\",\"caredx\",\"guardant health\",\"illumina\",\"natera\",\"sequoia capital\",\"stanford university\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"TechCrunch\",\"logo\":{\"@type\":\"imageObject\",\"url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/themes\\/techcrunch-2017\\/images\\/logo-json-ld.png\",\"width\":\"600\",\"height\":\"60\"}}}\n\t</script>\n<!-- END wp-parsely Plugin Version 1.13.0 -->\n<meta content=\"187288694643718\" property=\"fb:app_id\"/>\n<meta content=\"8062627951\" property=\"fb:pages\"/>\n<meta content=\"8803025,726995222,771265067,1550970059,1661021707,1178144075,643979435,852465367,4700188\" property=\"fb:admins\"/>\n<meta content=\"https://www.facebook.com/techcrunch\" property=\"article:publisher\"/>\n<meta content=\"TechCrunch\" property=\"og:site_name\"/>\n<meta content=\"social.techcrunch.com\" property=\"og:site\"/>\n<meta content=\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing\" property=\"og:title\"/>\n<meta content=\"This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that ha\u2026\" property=\"og:description\"/>\n<meta content=\"https://techcrunch.com/wp-content/uploads/2016/03/boxing-gloves-businessman.jpg?w=600\" property=\"og:image\"/>\n<meta content=\"http://social.techcrunch.com/2019/03/26/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing/\" property=\"og:url\"/>\n<meta content=\"article\" property=\"og:type\"/>\n<meta content=\"summary_large_image\" name=\"twitter:card\"/>\n<meta content=\"@techcrunch\" name=\"twitter:site\"/>\n<meta content=\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing\" name=\"twitter:title\"/>\n<meta content=\"This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks [\u2026]\" name=\"twitter:description\"/>\n<meta content=\"https://techcrunch.com/wp-content/uploads/2016/03/boxing-gloves-businessman.jpg?w=600\" name=\"twitter:image\"/>\n<script type=\"text/javascript\">var ajaxurl = \"https://techcrunch.com/wp-admin/admin-ajax.php\"</script><link href=\"https://techcrunch.com/2019/03/26/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing/amp/\" rel=\"amphtml\"/><link href=\"https://techcrunch.com/wp-content/uploads/2015/02/cropped-cropped-favicon-gradient.png?w=32\" rel=\"icon\" sizes=\"32x32\">\n<link href=\"https://techcrunch.com/wp-content/uploads/2015/02/cropped-cropped-favicon-gradient.png?w=192\" rel=\"icon\" sizes=\"192x192\"/>\n<link href=\"https://techcrunch.com/wp-content/uploads/2015/02/cropped-cropped-favicon-gradient.png?w=180\" rel=\"apple-touch-icon-precomposed\"/>\n<meta content=\"https://techcrunch.com/wp-content/uploads/2015/02/cropped-cropped-favicon-gradient.png?w=270\" name=\"msapplication-TileImage\"/>\n<script src=\"https://s.aolcdn.com/ads/adsWrapper.js\" type=\"text/javascript\"></script>\n<script type=\"text/javascript\">\n\ttry{adsEnableSandbox();}catch(e){}\n</script>\n</link></meta></meta></link></link></meta></head>\n<body class=\"\">\n<div id=\"root\">\n<div><!-- duplicate React-root div for styling -->\n<div class=\"content\">\n<article class=\"article-container article--post\">\n<header class=\"article__header\">\n<div class=\"article__title-wrapper\">\n<h1 class=\"article__title\">A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing</h1>\n</div>\n<div class=\"article__byline-wrapper\">\n<div class=\"article__byline\">\n<a href=\"https://techcrunch.com/author/connie-loizos/\">\n\t\t\tConnie Loizos\t\t</a>\n<span class=\"article__byline__meta\">\n<a href=\"https://twitter.com/Cookie\">@Cookie</a>\n<span class=\"text--green\"> / </span>\n\t\t\t\t\t\t1 week\t\t</span>\n</div>\n</div>\n<div class=\"article__featured-image-wrapper breakout\">\n<img class=\"article__featured-image\" src=\"https://techcrunch.com/wp-content/uploads/2016/03/boxing-gloves-businessman.jpg?w=600\"/>\n</div>\n</header>\n<div class=\"article-content\">\n<p id=\"speakable-summary\">This morning, a publicly traded transplant diagnostics company called <a href=\"https://www.caredxinc.com/\">CareDx</a>, along with Stanford University, sued another publicly traded genetic testing company, <a href=\"https://www.natera.com/\">Natera</a>, for patent infringement.</p>\n<p>Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks poised to play center stage again in future corporate battles.</p>\n<p>Loosely defined, cell-free DNA (or cfDNA) technology involves blood tests that enable physicians to understand what\u2019s happening in someone\u2019s body. They\u2019re not looking at red or white blood cells (thus the \u201ccell free\u201d part) but at plasma, which carries pieces of broken-up DNA, among other things.</p>\n<p>Companies like <a href=\"https://www.investors.com/news/technology/guardant-health-ipo/\">newly</a> public <a href=\"https://guardanthealth.com/\">Guardant Health</a> are using it to try to ensure that cancer patients receive the right drugs. Prenatal cfDNA screening has meanwhile become a common way to screen for specific chromosomal problems in a developing baby \u2014 including Down syndrome, trisomy 13 and trisomy 18. The latter has become particularly popular as an alternative to amniocentesis, a more intrusive, and sometimes high-risk, procedure in which a small amount of amniotic fluid is sampled from the amniotic sac surrounding a developing fetus.</p>\n<p>Yet another way that cfDNA testing can monitor clinical conditions and make a major impact on healthcare is by distinguishing the relative proportion of DNA molecules in a patient\u2019s blood after that person has had an organ transplant. Though traditionally, recipients have had to undergo biopsies to gauge whether or not their new organ was being accepted or rejected, it\u2019s now possible to measure through the far-less traumatic process of providing blood samples. (Broadly speaking, if, over time, the amount of donor DNA increases in the patient\u2019s blood, things aren\u2019t going well.)</p>\n<p>It\u2019s an important, if relatively new, development, and CareDx, a 19-year-old, Brisbane, Calif.-based company that went public in 2014, claims in its newly filed lawsuit that two patents it controls give it the exclusive right to non-invasively diagnose graft rejection in a great many organ transplant patients via cfDNA testing. What we mean: <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=9845497.PN.&amp;OS=PN/9845497&amp;RS=PN/9845497\">one of the patents</a> covers \u201ckidney transplant, a heart transplant, a liver transplant, a pancreas transplant, a lung transplant, a skin transplant, and any combination thereof.\u201d The <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=8703652.PN.&amp;OS=PN/8703652&amp;RS=PN/8703652\">second patent</a> covers 16 different methods, devices, compositions and kits for diagnosing or predicting transplant status or patient outcome.</p>\n<p>The patents were awarded in recent years to Stanford academics, including Stephen Quake, a renowned professor of bioengineering and applied physics. Though Stanford owns the patents, however, it licenses them to CareDx, and they\u2019ve dramatically enhanced the company\u2019s prospects. Indeed, while its shares were priced at $10 apiece at the time of its IPO, they\u2019ve been trading at $40 each more recently, thanks largely to its <a href=\"http://www.allosure.com/\">AlloSure</a> test, which is designed specifically for kidney transplant patients and, critically, is now covered by Medicare.</p>\n<p>Indeed, CareDx\u2019s lawsuit against 15-year-old <a class=\"crunchbase-link\" data-entity=\"natera\" data-type=\"organization\" href=\"https://crunchbase.com/organization/natera\" target=\"_blank\">Natera, <span class=\"crunchbase-tooltip-indicator\"></span></a> which went public in 2015, accuses it of \u201cpreparing to develop and commercialize\u201d a too-similar kidney transplant rejection test beginning in the middle of last year. It\u2019s seeking cash compensation and a court order that blocks the sale of Natera\u2019s offering.</p>\n<p>It\u2019s an offensive move, too, seemingly, given all those other organs at stake and the markets they could unlock.</p>\n<p>Natera, which counts <a class=\"crunchbase-link\" data-entity=\"sequoia-capital\" data-type=\"organization\" href=\"https://crunchbase.com/organization/sequoia-capital\" target=\"_blank\">Sequoia Capital\u2019s <span class=\"crunchbase-tooltip-indicator\"></span></a> Roelof Botha as a board member, did not provide an executive to comment on the suit. Botha also declined through a Sequoia spokesperson to comment. But Natera told us in a statement that it\u2019s \u201cconfident that we will prevail in this suit should it proceed and do not expect this suit to impact our commercialization plans or disrupt our operations in any way.\u201d Added the company, \u201cWe are not surprised that CareDx would attempt to disrupt the imminent commercialization of Natera\u2019s innovative organ transplant rejection test, which does not require donor genotyping, and will compete with CareDx\u2019s older test. In recently published studies, Natera demonstrated superior analytical and clinical test performance.\u201d</p>\n<p>What happens next remains to be seen, but it\u2019s not the first imbroglio in which Natera finds itself.\u00a0 A year ago, the gene-testing company <a class=\"crunchbase-link\" data-entity=\"illumina\" data-type=\"organization\" href=\"https://crunchbase.com/organization/illumina\" target=\"_blank\">Illumina <span class=\"crunchbase-tooltip-indicator\"></span></a> filed a lawsuit against Natera, alleging that the company\u2019s non-invasive prenatal testing infringes a patent that Illumina controls and that relies on analysis of cell-free DNA present in maternal blood. That case is still <a href=\"https://ecf.cand.uscourts.gov/doc1/035117771847\">moving toward a trial</a>. In the meantime, Illumina last year separately won a <a href=\"https://www.sdbj.com/news/2018/jan/29/illumina-awarded-267-million-patent-infringement-l/\">$26.7 million jury verdict</a> in a lawsuit accusing a subsidiary of Roche Holdings of using patented prenatal testing technology without authorization.</p>\n<p>Last year, Natera also agreed to pay <a href=\"https://www.genomeweb.com/molecular-diagnostics/natera-settles-billing-lawsuit-us-government-114m#.XJpsaetKiL8\">$11.4 million</a> to settle a lawsuit with the U.S. government, after it alleged that Natera submitted false claims to several government health programs based on tips by two former Natera employees who filed an earlier whistleblower lawsuit against the company.</p>\n<p>Natera \u2014 whose founding CEO, Matthew Rabinowitz, stepped down from his position in January of this year, replaced by longtime Natera employee and COO Steve Chapman \u2014 denied the allegations and, as part of the settlement terms, did not admit any wrongdoing.</p>\n<p>Either way, Natera, CareDx and Illumina aren\u2019t the only ones duking it out over cell-free DNA testing.</p>\n<p>In 2017, for example, Guardant <a href=\"https://www.genomeweb.com/business-news/guardant-health-sues-foundation-medicine-false-advertising#.XJp2TOtKiL8\">filed a lawsuit</a> against rival Foundation Medicine, alleging that Foundation\u2019s advertising for its own liquid and tissue tests harmed both Guardant and cancer patients by misleading oncologists about the relative accuracy and sensitivity of the competing genomic tests. Foundation later <a href=\"https://www.genomeweb.com/cancer/foundation-medicine-sues-guardant-health-patent-infringement\" rel=\"noopener noreferrer\" target=\"_blank\">sued Guardant</a>, alleging infringement of a patent that covers methods for analyzing a cancer patient\u2019s tissue or blood sample to detect multiple classes of genomic alterations.</p>\n<p>The two companies <a href=\"http://investors.foundationmedicine.com/news-releases/news-release-details/foundation-medicine-and-guardant-health-agree-settle-patent\">later settled</a> both without disclosing the terms of their agreement, but Guardant has more recently <a href=\"https://www.pacermonitor.com/public/case/22954496/Guardant_Health,_Inc_v_Foundation_Medicine,_Inc\">sued Foundation again</a>. It is also embroiled in an <a href=\"https://insight.rpxcorp.com/litigation_documents/12851668\">ongoing lawsuit</a> against another rival called Personal Genome Diagnostics over its cell-free DNA technology.</p>\n</div>\n<footer class=\"article-footer\">\n<input class=\"shortlink\" readonly=\"\" title=\"Article Shortlink\" type=\"text\" value=\"\"/>\n</footer>\n</article>\n</div>\n</div><!-- end React-root duplication div -->\n</div><!--end #root-->\n<noscript style=\"display:none;\">\n<img alt=\"\" height=\"1\" src=\"https://www.facebook.com/tr?id=1447508128842484&amp;ev=PageView&amp;noscript=1\" width=\"1\"/>\n</noscript>\n<script type=\"text/javascript\">\n\t\t// Configure the PARSELY window global to disable auto-tracking.\n\t\t// Must load before the Parse.ly script itself.\n\t\twindow.PARSELY = {\n\t\t\tautotrack: false,\n\t\t\tonload:    this.onload,\n\t\t};\n\t</script>\n<script data-parsely-site=\"techcrunch.com\" id=\"parsely-cfg\" src=\"//d1z2jf7jlzjs58.cloudfront.net/keys/techcrunch.com/p.js\"></script>\n<!-- JSON-LD -->\n<script type=\"application/ld+json\">\n\t\t{\"@context\":\"http:\\/\\/schema.org\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"TechCrunch\",\"logo\":{\"@type\":\"imageObject\",\"url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/themes\\/techcrunch-2017\\/images\\/logo-json-ld.png\",\"width\":\"600\",\"height\":\"60\"}},\"@type\":\"NewsArticle\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\\/\\/techcrunch.com\\/2019\\/03\\/26\\/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\\/\"},\"headline\":\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=680\",\"width\":680,\"height\":453},\"datePublished\":\"2019-03-26T21:36:29+00:00\",\"dateModified\":\"2019-04-04T17:47:30+00:00\",\"author\":[{\"@type\":\"Person\",\"name\":\"Connie Loizos\"}],\"description\":\"This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks [&hellip;]\",\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\".alpha\",\"#speakable-summary\"]}}\t</script>\n<!-- End JSON-LD -->\n<script src=\"https://use.typekit.net/svv7knm.js\" type=\"text/javascript\"></script>\n<script type=\"text/javascript\">\ntry{Typekit.load({ async: true });}catch(e){}\n</script>\n<script type=\"text/javascript\">\n/* <![CDATA[ */\nvar tc_app_data = {\"ads\":{\"adpage\":\"https:\\/\\/techcrunch.com\\/wp-content\\/themes\\/techcrunch-2017\\/features\\/ads\\/_uac\\/adpage.html\",\"gemini_enabled\":true,\"gemini_codes\":{\"position_4\":{\"mobile\":\"ae64471c-14c2-4457-8e9b-a5190206eafd\",\"desktop\":\"b2018d9e-dedc-4e85-8823-b06917beb892\"},\"position_8\":{\"mobile\":\"619392a1-b497-4aa9-b683-24aab7246c16\",\"desktop\":\"05c0b21d-e742-494d-ac59-474e3feaa4b8\"}},\"mns\":[{\"where\":\"*\",\"placements\":{\"native\":\"93501877\",\"mobile_native\":\"93501878\",\"leaderboard\":\"93484975\",\"rightrail\":\"93484976\",\"rightrail_on_view\":\"93484977\",\"mobile_300x250\":\"93484973\",\"mobile_dynamic\":\"93484974\",\"amp\":\"93523784\",\"inline_leaderboard\":\"93484932\",\"inline_mobile_300x250\":\"93484930\",\"inline_amp\":\"963874680\"}},{\"where\":{\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93484953\"}},{\"where\":{\"post_type\":[\"tc_sponsored_post\"]},\"placements\":{\"leaderboard\":\"963872468\",\"leaderboard_on_view\":\"963872469\",\"rightrail\":\"963872467\",\"rightrail_on_view\":\"963872467\",\"mobile_320x50\":\"963872466\",\"mobile_dynamic\":\"963872466\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"crunchbase-video-hub\"]},\"placements\":{\"mobile_300x250\":\"93487470\",\"mobile_dynamic\":\"93487469\",\"leaderboard\":\"93487468\",\"rightrail\":\"93487467\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"enterprise\"]},\"placements\":{\"mobile_300x250\":\"93484901\",\"mobile_dynamic\":\"93484902\",\"leaderboard\":\"93484903\",\"rightrail\":\"93484904\",\"rightrail_on_view\":\"93484905\",\"amp\":\"93523756\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"enterprise\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93512990\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"gadgets\"]},\"placements\":{\"mobile_300x250\":\"93484912\",\"mobile_dynamic\":\"93484913\",\"leaderboard\":\"93484914\",\"rightrail\":\"93484915\",\"rightrail_on_view\":\"93484916\",\"amp\":\"93523764\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"gadgets\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93513296\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"mobile\"]},\"placements\":{\"mobile_native\":\"93484962\",\"mobile_300x250\":\"93484960\",\"mobile_dynamic\":\"93484961\",\"leaderboard\":\"93484957\",\"rightrail\":\"93484958\",\"rightrail_on_view\":\"93484959\",\"amp\":\"93523763\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"mobile\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93510142\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"startups\"]},\"placements\":{\"gallery_300x250\":\"93511985\",\"mobile_300x250\":\"93484986\",\"mobile_dynamic\":\"93484987\",\"leaderboard\":\"93484988\",\"rightrail\":\"93484989\",\"rightrail_on_view\":\"93484990\",\"amp\":\"93523762\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"startups\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93511984\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"apps\"]},\"placements\":{\"mobile_300x250\":\"963891138\",\"mobile_dynamic\":\"963891134\",\"leaderboard\":\"963891132\",\"rightrail\":\"963891133\",\"rightrail_on_view\":\"963891136\",\"amp\":\"963891137\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"mobile\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"963891131\"}},{\"where\":{\"post_type\":[\"tc_marketing\"]},\"placements\":{\"mobile_dynamic\":\"93484859\",\"leaderboard\":\"93484860\",\"leaderboard_on_view\":\"93484861\",\"rightrail\":\"93484862\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"apple\"]},\"placements\":{\"mobile_300x250\":\"93484869\",\"mobile_dynamic\":\"93484870\",\"leaderboard\":\"93484866\",\"rightrail\":\"93484867\",\"rightrail_on_view\":\"93484868\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"back-to-school\",\"backtoschool\",\"backtoschool13\"]},\"placements\":{\"mobile_300x250\":\"93484871\",\"mobile_dynamic\":\"93484872\",\"leaderboard\":\"93484873\",\"rightrail\":\"93484874\",\"rightrail_on_view\":\"93484875\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"ces\"]},\"placements\":{\"gallery_300x250\":\"963853166\",\"mobile_300x250\":\"93484876\",\"mobile_dynamic\":\"93484877\",\"leaderboard\":\"93484878\",\"rightrail\":\"93484879\",\"rightrail_on_view\":\"93484880\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"ces\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"963853167\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"disrupt\"]},\"placements\":{\"mobile_300x250\":\"93484895\",\"mobile_dynamic\":\"93484896\",\"leaderboard\":\"93484897\",\"rightrail\":\"93484898\",\"rightrail_on_view\":\"93484899\",\"amp\":\"93523765\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"gift-guide-2018\"]},\"placements\":{\"gallery_300x250\":\"93518231\",\"mobile_300x250\":\"93484930\",\"mobile_dynamic\":\"93484931\",\"leaderboard\":\"93484932\",\"rightrail\":\"93484933\",\"rightrail_on_view\":\"93484934\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"gift-guide-2018\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93518230\"}},{\"where\":{\"url\":\"\\/pages\\/gift-guide-2018\\/\"},\"placements\":{\"gallery_300x250\":\"93518231\",\"mobile_300x250\":\"93484930\",\"mobile_dynamic\":\"93484931\",\"leaderboard\":\"93484932\",\"rightrail\":\"93484933\",\"rightrail_on_view\":\"93484934\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"sxsw\"]},\"placements\":{\"gallery_300x250\":\"963858038\",\"mobile_300x250\":\"963858040\",\"mobile_dynamic\":\"963858041\",\"leaderboard\":\"963858042\",\"rightrail\":\"963858043\",\"rightrail_on_view\":\"963858044\"}},{\"where\":{\"taxonomy\":\"post_tag\",\"terms\":[\"sxsw\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"963858039\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"tc_video\"]},\"placements\":{\"leaderboard\":\"963874666\",\"rightrail\":\"963874667\",\"rightrail_on_view\":\"963874668\",\"mobile_320x50\":\"93485001\",\"mobile_300x250\":\"93485000\",\"mobile_dynamic\":\"93484943\",\"amp\":\"93523757\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"developer\"]},\"placements\":{\"gallery_300x250\":\"93510995\",\"mobile_300x250\":\"93484890\",\"mobile_dynamic\":\"93484891\",\"leaderboard\":\"93484892\",\"rightrail\":\"93484893\",\"rightrail_on_view\":\"93484894\",\"amp\":\"93523761\"}},{\"where\":{\"taxonomy\":\"category\",\"terms\":[\"developer\"],\"post_type\":[\"tc-media-gallery\"]},\"placements\":{\"leaderboard\":\"93510992\"}},{\"where\":{\"url\":\"\\/video\\/\"},\"placements\":{\"leaderboard\":\"963874666\",\"rightrail\":\"963874667\",\"rightrail_on_view\":\"963874668\",\"mobile_320x50\":\"93485001\",\"mobile_300x250\":\"93485000\",\"mobile_dynamic\":\"93484943\",\"amp\":\"93523757\"}},{\"where\":{\"url\":\"\\/(page\\/\\\\d+)?\"},\"placements\":{\"native\":\"93484857\",\"leaderboard\":\"93484945\",\"rightrail\":\"93484946\",\"rightrail_on_view\":\"93484947\",\"amp\":\"93523758\",\"mobile_native\":\"93484858\",\"mobile_300x250\":\"93484942\",\"mobile_dynamic\":\"93484943\"}}]},\"assetURI\":\"https:\\/\\/techcrunch.com\\/wp-content\\/themes\\/techcrunch-2017\",\"breaking\":\"\",\"live_event\":\"0\",\"livestream_hash\":null,\"feature_island\":[],\"isAdminBar\":\"\",\"marketoEventId\":\"1004\",\"marketoBrandStudioId\":\"1740\",\"menus\":{\"main\":[{\"id\":335981,\"order\":1,\"parent\":0,\"text\":\"Startups\",\"url\":\"https:\\/\\/techcrunch.com\\/startups\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":20429,\"object\":\"category\",\"type\":\"taxonomy\",\"type_label\":\"Category\",\"children\":[]},{\"id\":1599989,\"order\":2,\"parent\":0,\"text\":\"Apps\",\"url\":\"https:\\/\\/techcrunch.com\\/apps\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":449557102,\"object\":\"category\",\"type\":\"taxonomy\",\"type_label\":\"Category\",\"children\":[]},{\"id\":335983,\"order\":3,\"parent\":0,\"text\":\"Gadgets\",\"url\":\"https:\\/\\/techcrunch.com\\/gadgets\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":449557086,\"object\":\"category\",\"type\":\"taxonomy\",\"type_label\":\"Category\",\"children\":[]},{\"id\":335986,\"order\":4,\"parent\":0,\"text\":\"Videos\",\"url\":\"\\/video\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":335986,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1761192,\"order\":5,\"parent\":0,\"text\":\"Podcasts\",\"url\":\"https:\\/\\/techcrunch.com\\/pages\\/podcasts\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1760429,\"object\":\"page\",\"type\":\"post_type\",\"type_label\":\"Page\",\"children\":[]},{\"id\":1781882,\"order\":6,\"parent\":0,\"text\":\"Extra Crunch\",\"url\":\"\\/extracrunch\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1781882,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1599991,\"order\":7,\"parent\":0,\"text\":\"\\u2014\",\"url\":\"#\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1599991,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1599990,\"order\":8,\"parent\":0,\"text\":\"Events\",\"url\":\"\\/events\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1599990,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1752899,\"order\":9,\"parent\":0,\"text\":\"Advertise\",\"url\":\"https:\\/\\/techcrunch.com\\/pages\\/advertisement-events-calendar\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1416499,\"object\":\"page\",\"type\":\"post_type\",\"type_label\":\"Page\",\"children\":[]},{\"id\":1599992,\"order\":10,\"parent\":0,\"text\":\"Crunchbase\",\"url\":\"http:\\/\\/crunchbase.com\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1599992,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}],\"submenu\":[{\"id\":1599997,\"order\":1,\"parent\":0,\"text\":\"Topics\",\"url\":\"#\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1599997,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[{\"id\":1600003,\"order\":2,\"parent\":1599997,\"text\":\"Social\",\"url\":\"https:\\/\\/techcrunch.com\\/social\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"How technology is shaping the way we live with each other\",\"object_id\":3457,\"object\":\"category\",\"type\":\"taxonomy\",\"type_label\":\"Category\",\"children\":[]},{\"id\":1600004,\"order\":3,\"parent\":1599997,\"text\":\"Mobile\",\"url\":\"https:\\/\\/techcrunch.com\\/mobile\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"The apps, platforms and businesses redefining how we use computers\",\"object_id\":449557028,\"object\":\"category\",\"type\":\"taxonomy\",\"type_label\":\"Category\",\"children\":[]},{\"id\":1600005,\"order\":4,\"parent\":1599997,\"text\":\"Enterprise\",\"url\":\"https:\\/\\/techcrunch.com\\/enterprise\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"How cloud computing, big data and new devices are changing work\",\"object_id\":449557044,\"object\":\"category\",\"type\":\"taxonomy\",\"type_label\":\"Category\",\"children\":[]}]},{\"id\":1599998,\"order\":5,\"parent\":0,\"text\":\"About\",\"url\":\"#\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1599998,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[{\"id\":1601717,\"order\":6,\"parent\":1599998,\"text\":\"Staff\",\"url\":\"\\/pages\\/about-techcrunch\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1601717,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1600007,\"order\":7,\"parent\":1599998,\"text\":\"Contact Us\",\"url\":\"https:\\/\\/techcrunch.com\\/pages\\/contact-us\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":672,\"object\":\"page\",\"type\":\"post_type\",\"type_label\":\"Page\",\"children\":[]},{\"id\":1600006,\"order\":8,\"parent\":1599998,\"text\":\"Advertising Opportunities\",\"url\":\"https:\\/\\/techcrunch.com\\/pages\\/advertisement-events-calendar\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1416499,\"object\":\"page\",\"type\":\"post_type\",\"type_label\":\"Page\",\"children\":[]}]},{\"id\":1600000,\"order\":9,\"parent\":0,\"text\":\"More TechCrunch\",\"url\":\"#\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600000,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[{\"id\":1600009,\"order\":10,\"parent\":1600000,\"text\":\"Startup Battlefield\",\"url\":\"\\/startup-battlefield\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600009,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1795710,\"order\":11,\"parent\":1600000,\"text\":\"Sponsored Content\",\"url\":\"\\/sponsored\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1795710,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1600010,\"order\":12,\"parent\":1600000,\"text\":\"Include\",\"url\":\"\\/include\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600010,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1600012,\"order\":13,\"parent\":1600000,\"text\":\"Crunchboard\",\"url\":\"http:\\/\\/crunchboard.com\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600012,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1600011,\"order\":14,\"parent\":1600000,\"text\":\"TechCrunch Store\",\"url\":\"http:\\/\\/techcrunchstore.com\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600011,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1620756,\"order\":15,\"parent\":1600000,\"text\":\"Apply to Startup Events\",\"url\":\"https:\\/\\/techcrunch.com\\/pages\\/tc-startup-programs\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1617703,\"object\":\"page\",\"type\":\"post_type\",\"type_label\":\"Page\",\"children\":[]}]},{\"id\":1600001,\"order\":16,\"parent\":0,\"text\":\"Read Anywhere\",\"url\":\"#\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600001,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[{\"id\":1600013,\"order\":17,\"parent\":1600001,\"text\":\"App Store\",\"url\":\"https:\\/\\/itunes.apple.com\\/us\\/app\\/techcrunch\\/id526058642?mt=8\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600013,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1600014,\"order\":18,\"parent\":1600001,\"text\":\"Google Play\",\"url\":\"https:\\/\\/play.google.com\\/store\\/apps\\/details?id=com.aol.mobile.techcrunch\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600014,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}]},{\"id\":1600002,\"order\":19,\"parent\":0,\"text\":\"International\",\"url\":\"#\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600002,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[{\"id\":1600015,\"order\":20,\"parent\":1600002,\"text\":\"China\",\"url\":\"http:\\/\\/techcrunch.cn\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600015,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1600016,\"order\":21,\"parent\":1600002,\"text\":\"Japan\",\"url\":\"http:\\/\\/jp.techcrunch.com\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1600016,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}]}],\"footer\":[{\"id\":1787716,\"order\":1,\"parent\":0,\"text\":\"TechCrunch\",\"url\":\"https:\\/\\/techcrunch.com\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1787716,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1601925,\"order\":2,\"parent\":0,\"text\":\"Privacy Policy\",\"url\":\"https:\\/\\/policies.oath.com\\/xw\\/en\\/oath\\/privacy\\/intl\\/index.html\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1601925,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1601926,\"order\":3,\"parent\":0,\"text\":\"About Our Ads\",\"url\":\"http:\\/\\/adinfo.aol.com\\/about-our-ads\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1601926,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1687671,\"order\":4,\"parent\":0,\"text\":\"Code of Conduct\",\"url\":\"https:\\/\\/techcrunch.com\\/pages\\/code-of-conduct\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1678717,\"object\":\"page\",\"type\":\"post_type\",\"type_label\":\"Page\",\"children\":[]},{\"id\":1601928,\"order\":5,\"parent\":0,\"text\":\"Terms of Service\",\"url\":\"https:\\/\\/policies.oath.com\\/xw\\/en\\/oath\\/terms\\/otos\\/index.html\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1601928,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}],\"include\":[{\"id\":1601974,\"order\":1,\"parent\":0,\"text\":\"Our Mission\",\"url\":\"\\/include\\/mission-statement\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1601974,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1601975,\"order\":2,\"parent\":0,\"text\":\"Office Hours\",\"url\":\"\\/include\\/office-hours\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1601975,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}],\"startup-battlefield\":[{\"id\":1602061,\"order\":1,\"parent\":0,\"text\":\"About\",\"url\":\"\\/startup-battlefield\\/about\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1602061,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1602062,\"order\":2,\"parent\":0,\"text\":\"FAQ\",\"url\":\"\\/startup-battlefield\\/faq\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1602062,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1602063,\"order\":3,\"parent\":0,\"text\":\"Leaderboard\",\"url\":\"\\/startup-battlefield\\/leaderboard\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1602063,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1602065,\"order\":4,\"parent\":0,\"text\":\"Battlefield Home\",\"url\":\"\\/startup-battlefield\\/\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1602065,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1787197,\"order\":5,\"parent\":0,\"text\":\"Apply Now\",\"url\":\"https:\\/\\/apply.techcrunch.com\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"apply-now-link\"],\"description\":\"\",\"object_id\":1787197,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}],\"video-hub\":[{\"id\":1605165,\"order\":1,\"parent\":0,\"text\":\"News\",\"url\":\"\\/shows\\/tctv-news\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605165,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605166,\"order\":2,\"parent\":0,\"text\":\"Gadgets\",\"url\":\"\\/shows\\/gadgets\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605166,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605167,\"order\":3,\"parent\":0,\"text\":\"Features\",\"url\":\"\\/shows\\/features\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605167,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605168,\"order\":4,\"parent\":0,\"text\":\"Reviews\",\"url\":\"\\/shows\\/reviews\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605168,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605169,\"order\":5,\"parent\":0,\"text\":\"Interviews\",\"url\":\"\\/shows\\/interviews\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605169,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605170,\"order\":6,\"parent\":0,\"text\":\"Apps\",\"url\":\"\\/shows\\/apps\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605170,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605171,\"order\":7,\"parent\":0,\"text\":\"Disrupt\",\"url\":\"\\/shows\\/techcrunch-disrupt\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605171,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605172,\"order\":8,\"parent\":0,\"text\":\"Battlefield\",\"url\":\"\\/shows\\/techcrunch-battlefield\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605172,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605173,\"order\":9,\"parent\":0,\"text\":\"Sessions\",\"url\":\"\\/shows\\/tc-sessions\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605173,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605174,\"order\":10,\"parent\":0,\"text\":\"Crunch Report\",\"url\":\"\\/shows\\/crunch-report\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605174,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605175,\"order\":11,\"parent\":0,\"text\":\"Judah vs the Machines\",\"url\":\"\\/shows\\/judah-vs-the-machines\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605175,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605176,\"order\":12,\"parent\":0,\"text\":\"Down Round\",\"url\":\"\\/shows\\/down-round\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605176,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605177,\"order\":13,\"parent\":0,\"text\":\"Trust Disrupted\",\"url\":\"\\/shows\\/trust-disrupted\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605177,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605178,\"order\":14,\"parent\":0,\"text\":\"Built in Brooklyn\",\"url\":\"\\/shows\\/built-in-brooklyn\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605178,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605179,\"order\":15,\"parent\":0,\"text\":\"Inside Jobs\",\"url\":\"\\/shows\\/inside-jobs\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605179,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]},{\"id\":1605180,\"order\":16,\"parent\":0,\"text\":\"TC Cribs\",\"url\":\"\\/shows\\/tc-cribs\",\"attr\":\"\",\"target\":\"\",\"classes\":[\"\"],\"description\":\"\",\"object_id\":1605180,\"object\":\"custom\",\"type\":\"custom\",\"type_label\":\"Custom Link\",\"children\":[]}]},\"playlistData\":{\"homepage\":[],\"videohub\":[]},\"entities\":{\"posts\":[{\"id\":1801038,\"date\":\"2019-03-26T14:36:29\",\"date_gmt\":\"2019-03-26T21:36:29\",\"guid\":{\"rendered\":\"https:\\/\\/techcrunch.com\\/?p=1801038\"},\"modified\":\"2019-04-04T10:47:30\",\"modified_gmt\":\"2019-04-04T17:47:30\",\"slug\":\"a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\",\"status\":\"publish\",\"type\":\"post\",\"link\":\"https:\\/\\/techcrunch.com\\/2019\\/03\\/26\\/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\\/\",\"title\":{\"rendered\":\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing\"},\"content\":{\"rendered\":\"<p id=\\\"speakable-summary\\\">This morning, a publicly traded transplant diagnostics company called <a href=\\\"https:\\/\\/www.caredxinc.com\\/\\\">CareDx<\\/a>, along with Stanford University, sued another publicly traded genetic testing company, <a href=\\\"https:\\/\\/www.natera.com\\/\\\">Natera<\\/a>, for patent infringement.<\\/p>\\n<p>Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks poised to play center stage again in future corporate battles.<\\/p>\\n<p>Loosely defined, cell-free DNA (or cfDNA) technology involves blood tests that enable physicians to understand what&#8217;s happening in someone&#8217;s body. They&#8217;re not looking at red or white blood cells (thus the &#8220;cell free&#8221; part) but at plasma, which carries pieces of broken-up DNA, among other things.<\\/p>\\n<p>Companies like <a href=\\\"https:\\/\\/www.investors.com\\/news\\/technology\\/guardant-health-ipo\\/\\\">newly<\\/a> public <a href=\\\"https:\\/\\/guardanthealth.com\\/\\\">Guardant Health<\\/a> are using it to try to ensure that cancer patients receive the right drugs. Prenatal cfDNA screening has meanwhile become a common way to screen for specific chromosomal problems in a developing baby &#8212; including Down syndrome, trisomy 13 and trisomy 18. The latter has become particularly popular as an alternative to amniocentesis, a more intrusive, and sometimes high-risk, procedure in which a small amount of amniotic fluid is sampled from the amniotic sac surrounding a developing fetus.<\\/p>\\n<p>Yet another way that cfDNA testing can monitor clinical conditions and make a major impact on healthcare is by distinguishing the relative proportion of DNA molecules in a patient&#8217;s blood after that person has had an organ transplant. Though traditionally, recipients have had to undergo biopsies to gauge whether or not their new organ was being accepted or rejected, it&#8217;s now possible to measure through the far-less traumatic process of providing blood samples. (Broadly speaking, if, over time, the amount of donor DNA increases in the patient&#8217;s blood, things aren&#8217;t going well.)<\\/p>\\n<p>It&#8217;s an important, if relatively new, development, and CareDx, a 19-year-old, Brisbane, Calif.-based company that went public in 2014, claims in its newly filed lawsuit that two patents it controls give it the exclusive right to non-invasively diagnose graft rejection in a great many organ transplant patients via cfDNA testing. What we mean: <a href=\\\"http:\\/\\/patft.uspto.gov\\/netacgi\\/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=9845497.PN.&amp;OS=PN\\/9845497&amp;RS=PN\\/9845497\\\">one of the patents<\\/a> covers &#8220;kidney transplant, a heart transplant, a liver transplant, a pancreas transplant, a lung transplant, a skin transplant, and any combination thereof.&#8221; The <a href=\\\"http:\\/\\/patft.uspto.gov\\/netacgi\\/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=8703652.PN.&amp;OS=PN\\/8703652&amp;RS=PN\\/8703652\\\">second patent<\\/a> covers 16 different methods, devices, compositions and kits for diagnosing or predicting transplant status or patient outcome.<\\/p>\\n<p>The patents were awarded in recent years to Stanford academics, including Stephen Quake, a renowned professor of bioengineering and applied physics. Though Stanford owns the patents, however, it licenses them to CareDx, and they&#8217;ve dramatically enhanced the company&#8217;s prospects. Indeed, while its shares were priced at $10 apiece at the time of its IPO, they&#8217;ve been trading at $40 each more recently, thanks largely to its <a href=\\\"http:\\/\\/www.allosure.com\\/\\\">AlloSure<\\/a> test, which is designed specifically for kidney transplant patients and, critically, is now covered by Medicare.<\\/p>\\n<p>Indeed, CareDx&#8217;s lawsuit against 15-year-old <a class=\\\"crunchbase-link\\\" href=\\\"https:\\/\\/crunchbase.com\\/organization\\/natera\\\" target=\\\"_blank\\\" data-type=\\\"organization\\\" data-entity=\\\"natera\\\">Natera, <span class=\\\"crunchbase-tooltip-indicator\\\"><\\/span><\\/a> which went public in 2015, accuses it of &#8220;preparing to develop and commercialize&#8221; a too-similar kidney transplant rejection test beginning in the middle of last year. It&#8217;s seeking cash compensation and a court order that blocks the sale of Natera&#8217;s offering.<\\/p>\\n<p>It&#8217;s an offensive move, too, seemingly, given all those other organs at stake and the markets they could unlock.<\\/p>\\n<p>Natera, which counts <a class=\\\"crunchbase-link\\\" href=\\\"https:\\/\\/crunchbase.com\\/organization\\/sequoia-capital\\\" target=\\\"_blank\\\" data-type=\\\"organization\\\" data-entity=\\\"sequoia-capital\\\">Sequoia Capital&#8217;s <span class=\\\"crunchbase-tooltip-indicator\\\"><\\/span><\\/a> Roelof Botha as a board member, did not provide an executive to comment on the suit. Botha also declined through a Sequoia spokesperson to comment. But Natera told us in a statement that it&#8217;s &#8220;confident that we will prevail in this suit should it proceed and do not expect this suit to impact our commercialization plans or disrupt our operations in any way.&#8221; Added the company, &#8220;We are not surprised that CareDx would attempt to disrupt the imminent commercialization of Natera\\u2019s innovative organ transplant rejection test, which does not require donor genotyping, and will compete with CareDx\\u2019s older test. In recently published studies, Natera demonstrated superior analytical and clinical test performance.&#8221;<\\/p>\\n<p>What happens next remains to be seen, but it&#8217;s not the first imbroglio in which Natera finds itself.\\u00a0 A year ago, the gene-testing company <a class=\\\"crunchbase-link\\\" href=\\\"https:\\/\\/crunchbase.com\\/organization\\/illumina\\\" target=\\\"_blank\\\" data-type=\\\"organization\\\" data-entity=\\\"illumina\\\">Illumina <span class=\\\"crunchbase-tooltip-indicator\\\"><\\/span><\\/a> filed a lawsuit against Natera, alleging that the company&#8217;s non-invasive prenatal testing infringes a patent that Illumina controls and that relies on analysis of cell-free DNA present in maternal blood. That case is still <a href=\\\"https:\\/\\/ecf.cand.uscourts.gov\\/doc1\\/035117771847\\\">moving toward a trial<\\/a>. In the meantime, Illumina last year separately won a <a href=\\\"https:\\/\\/www.sdbj.com\\/news\\/2018\\/jan\\/29\\/illumina-awarded-267-million-patent-infringement-l\\/\\\">$26.7 million jury verdict<\\/a> in a lawsuit accusing a subsidiary of Roche Holdings of using patented prenatal testing technology without authorization.<\\/p>\\n<p>Last year, Natera also agreed to pay <a href=\\\"https:\\/\\/www.genomeweb.com\\/molecular-diagnostics\\/natera-settles-billing-lawsuit-us-government-114m#.XJpsaetKiL8\\\">$11.4 million<\\/a> to settle a lawsuit with the U.S. government, after it alleged that Natera submitted false claims to several government health programs based on tips by two former Natera employees who filed an earlier whistleblower lawsuit against the company.<\\/p>\\n<p>Natera &#8212; whose founding CEO, Matthew Rabinowitz, stepped down from his position in January of this year, replaced by longtime Natera employee and COO Steve Chapman &#8212; denied the allegations and, as part of the settlement terms, did not admit any wrongdoing.<\\/p>\\n<p>Either way, Natera, CareDx and Illumina aren&#8217;t the only ones duking it out over cell-free DNA testing.<\\/p>\\n<p>In 2017, for example, Guardant <a href=\\\"https:\\/\\/www.genomeweb.com\\/business-news\\/guardant-health-sues-foundation-medicine-false-advertising#.XJp2TOtKiL8\\\">filed a lawsuit<\\/a> against rival Foundation Medicine, alleging that Foundation&#8217;s advertising for its own liquid and tissue tests harmed both Guardant and cancer patients by misleading oncologists about the relative accuracy and sensitivity of the competing genomic tests. Foundation later <a href=\\\"https:\\/\\/www.genomeweb.com\\/cancer\\/foundation-medicine-sues-guardant-health-patent-infringement\\\" target=\\\"_blank\\\" rel=\\\"noopener noreferrer\\\">sued Guardant<\\/a>, alleging infringement of a patent that covers methods for analyzing a cancer patient&#8217;s tissue or blood sample to detect multiple classes of genomic alterations.<\\/p>\\n<p>The two companies <a href=\\\"http:\\/\\/investors.foundationmedicine.com\\/news-releases\\/news-release-details\\/foundation-medicine-and-guardant-health-agree-settle-patent\\\">later settled<\\/a> both without disclosing the terms of their agreement, but Guardant has more recently <a href=\\\"https:\\/\\/www.pacermonitor.com\\/public\\/case\\/22954496\\/Guardant_Health,_Inc_v_Foundation_Medicine,_Inc\\\">sued Foundation again<\\/a>. It is also embroiled in an <a href=\\\"https:\\/\\/insight.rpxcorp.com\\/litigation_documents\\/12851668\\\">ongoing lawsuit<\\/a> against another rival called Personal Genome Diagnostics over its cell-free DNA technology.<\\/p>\\n\",\"protected\":false},\"excerpt\":{\"rendered\":\"<p>This morning, a publicly traded transplant diagnostics company called CareDx, along with Stanford University, sued another publicly traded genetic testing company, Natera, for patent infringement. Much appears to be at stake, and it all centers on cell-free DNA testing, a type of technology that has already been at the crux of numerous lawsuits and looks [&hellip;]<\\/p>\\n\",\"protected\":false},\"author\":89646803,\"featured_media\":1287084,\"comment_status\":\"open\",\"ping_status\":\"closed\",\"sticky\":false,\"template\":\"\",\"format\":\"standard\",\"meta\":{\"outcome\":\"\",\"status\":\"\",\"crunchbase_tag\":0,\"amp_status\":\"\",\"relegenceEntities\":[],\"relegenceSubjects\":[],\"jetpack_publicize_message\":\"A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing https:\\/\\/tcrn.ch\\/2TYZ1VF by @cookie\"},\"categories\":[337,576601753,17396],\"tags\":[576646100,213276350,2773040,576646101,245607,602846],\"crunchbase_tag\":[576646128],\"tc_stories_tax\":[],\"tc_event\":[],\"jetpack_featured_media_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg\",\"jetpack_publicize_connections\":[],\"shortlink\":\"https:\\/\\/tcrn.ch\\/2TYZ1VF\",\"rapidData\":{\"pt\":\"\",\"pct\":\"\"},\"featured\":false,\"subtitle\":\"\",\"fundingRound\":false,\"seoTitle\":\"\",\"seoDescription\":\"\",\"premiumContent\":false,\"premiumCutoffPercent\":1,\"tc_cb_mapping\":[{\"slug\":\"sequoia-capital\",\"cb_name\":\"Sequoia Capital\",\"cb_slug\":\"sequoia-capital-organization\",\"cb_link\":\"https:\\/\\/crunchbase.com\\/organization\\/sequoia-capital\"},{\"slug\":\"guardant-health\",\"cb_name\":\"Guardant Health\",\"cb_slug\":\"guardant-health-organization\",\"cb_link\":\"https:\\/\\/crunchbase.com\\/organization\\/guardant-health\"},{\"slug\":\"illumina\",\"cb_name\":\"Illumina\",\"cb_slug\":\"illumina-organization\",\"cb_link\":\"https:\\/\\/crunchbase.com\\/organization\\/illumina\"},{\"slug\":\"stanford-university\",\"cb_name\":\"Stanford University\",\"cb_slug\":\"stanford-university-organization\",\"cb_link\":\"https:\\/\\/crunchbase.com\\/organization\\/stanford-university\"},{\"slug\":\"natera\",\"cb_name\":\"Natera\",\"cb_slug\":\"natera-organization\",\"cb_link\":\"https:\\/\\/crunchbase.com\\/organization\\/natera\"}],\"associatedEvent\":null,\"event\":null,\"authors\":[89646803],\"hideFeaturedImage\":false,\"relatedArticles\":[],\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts\\/1801038\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/types\\/post\"}],\"version-history\":[{\"count\":28,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts\\/1801038\\/revisions\"}],\"predecessor-version\":[{\"id\":1802926,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts\\/1801038\\/revisions\\/1802926\"}],\"authors\":[{\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\\/89646803\"}],\"replies\":[{\"embeddable\":true,\"count\":0,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/comments?post=1801038&order=asc&tc_hierarchical=flat\"}],\"https:\\/\\/techcrunch.com\\/edit\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-admin\\/post.php?post=1801038&action=edit\"}],\"author\":[{\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\\/89646803\"}],\"wp:featuredmedia\":[{\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/media\\/1287084\"}],\"wp:attachment\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/media?parent=1801038\"}],\"wp:term\":[{\"taxonomy\":\"category\",\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories?post=1801038\"},{\"taxonomy\":\"post_tag\",\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags?post=1801038\"},{\"taxonomy\":\"_tc_cb_tag_taxonomy\",\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/crunchbase_tag?post=1801038\"},{\"taxonomy\":\"tc_stories_tax\",\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_stories_tax?post=1801038\"},{\"taxonomy\":\"tc_event\",\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_event?post=1801038\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]},\"_embedded\":{\"authors\":[{\"id\":89646803,\"name\":\"Connie Loizos\",\"url\":\"\",\"description\":\"\",\"link\":\"https:\\/\\/techcrunch.com\\/author\\/connie-loizos\\/\",\"slug\":\"connie-loizos\",\"avatar_urls\":{\"24\":\"https:\\/\\/secure.gravatar.com\\/avatar\\/52bc07c5a4dde8dabe873328ca360e36?s=24&d=identicon&r=g\",\"48\":\"https:\\/\\/secure.gravatar.com\\/avatar\\/52bc07c5a4dde8dabe873328ca360e36?s=48&d=identicon&r=g\",\"96\":\"https:\\/\\/secure.gravatar.com\\/avatar\\/52bc07c5a4dde8dabe873328ca360e36?s=96&d=identicon&r=g\"},\"links\":{\"homepage\":\"http:\\/\\/www.strictlyvc.com\\/\",\"twitter\":\"https:\\/\\/twitter.com\\/cookie\",\"linkedin\":\"http:\\/\\/www.linkedin.com\\/pub\\/connie-loizos\\/0\\/282\\/380\",\"crunchbase\":\"https:\\/\\/www.crunchbase.com\\/person\\/connie-loizos\"},\"position\":\"Silicon Valley Editor\",\"cbDescription\":\"<p>Loizos has been reporting on Silicon Valley since the late '90s, when she joined the original Red Herring magazine. She is currently the Silicon Valley Editor of TechCrunch. She's also the founder of StrictlyVC,  a daily e-newsletter and lecture series.<\\/p>\",\"cbAvatar\":\"https:\\/\\/crunchbase-production-res.cloudinary.com\\/image\\/upload\\/v1435774935\\/nyfwriukavsofyxvrqbt.png\",\"twitter\":\"cookie\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\\/89646803\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\"}]}}],\"author\":[{\"id\":89646803,\"name\":\"Connie Loizos\",\"url\":\"\",\"description\":\"\",\"link\":\"https:\\/\\/techcrunch.com\\/author\\/connie-loizos\\/\",\"slug\":\"connie-loizos\",\"avatar_urls\":{\"24\":\"https:\\/\\/secure.gravatar.com\\/avatar\\/52bc07c5a4dde8dabe873328ca360e36?s=24&d=identicon&r=g\",\"48\":\"https:\\/\\/secure.gravatar.com\\/avatar\\/52bc07c5a4dde8dabe873328ca360e36?s=48&d=identicon&r=g\",\"96\":\"https:\\/\\/secure.gravatar.com\\/avatar\\/52bc07c5a4dde8dabe873328ca360e36?s=96&d=identicon&r=g\"},\"links\":{\"homepage\":\"http:\\/\\/www.strictlyvc.com\\/\",\"twitter\":\"https:\\/\\/twitter.com\\/cookie\",\"linkedin\":\"http:\\/\\/www.linkedin.com\\/pub\\/connie-loizos\\/0\\/282\\/380\",\"crunchbase\":\"https:\\/\\/www.crunchbase.com\\/person\\/connie-loizos\"},\"position\":\"Silicon Valley Editor\",\"cbDescription\":\"<p>Loizos has been reporting on Silicon Valley since the late '90s, when she joined the original Red Herring magazine. She is currently the Silicon Valley Editor of TechCrunch. She's also the founder of StrictlyVC,  a daily e-newsletter and lecture series.<\\/p>\",\"cbAvatar\":\"https:\\/\\/crunchbase-production-res.cloudinary.com\\/image\\/upload\\/v1435774935\\/nyfwriukavsofyxvrqbt.png\",\"twitter\":\"cookie\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\\/89646803\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\"}]}}],\"wp:featuredmedia\":[{\"id\":1287084,\"date\":\"2016-03-06T19:28:49\",\"slug\":\"boxing-gloves-businessman\",\"type\":\"attachment\",\"link\":\"https:\\/\\/techcrunch.com\\/2016\\/03\\/07\\/separating-fact-from-fiction-at-disrupt-with-josh-kopelman-andy-weissman-and-chris-douvos\\/boxing-gloves-businessman\\/\",\"title\":{\"rendered\":\"boxing-gloves-businessman\"},\"author\":89646803,\"license\":\"\",\"authors\":[89646803],\"caption\":{\"rendered\":\"\"},\"alt_text\":\"\",\"media_type\":\"image\",\"mime_type\":\"image\\/jpeg\",\"media_details\":{\"width\":1500,\"height\":1000,\"file\":\"2016\\/03\\/boxing-gloves-businessman.jpg\",\"sizes\":{\"thumbnail\":{\"file\":\"boxing-gloves-businessman.jpg?resize=150,100\",\"width\":150,\"height\":100,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=150\"},\"medium\":{\"file\":\"boxing-gloves-businessman.jpg?resize=300,200\",\"width\":300,\"height\":200,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=300\"},\"medium_large\":{\"file\":\"boxing-gloves-businessman.jpg?resize=768,512\",\"width\":768,\"height\":512,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=1024\"},\"large\":{\"file\":\"boxing-gloves-businessman.jpg?resize=680,453\",\"width\":680,\"height\":453,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=680\"},\"guest-author-32\":{\"file\":\"boxing-gloves-businessman.jpg?resize=32,32\",\"width\":32,\"height\":32,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=32&h=32&crop=1\"},\"guest-author-50\":{\"file\":\"boxing-gloves-businessman.jpg?resize=50,50\",\"width\":50,\"height\":50,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=50&h=50&crop=1\"},\"guest-author-64\":{\"file\":\"boxing-gloves-businessman.jpg?resize=64,64\",\"width\":64,\"height\":64,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=64&h=64&crop=1\"},\"guest-author-96\":{\"file\":\"boxing-gloves-businessman.jpg?resize=96,96\",\"width\":96,\"height\":96,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=96&h=96&crop=1\"},\"guest-author-128\":{\"file\":\"boxing-gloves-businessman.jpg?resize=128,128\",\"width\":128,\"height\":128,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=128&h=128&crop=1\"},\"concierge-thumb\":{\"file\":\"boxing-gloves-businessman.jpg?resize=50,33\",\"width\":50,\"height\":33,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg?w=50\"},\"full\":{\"file\":\"boxing-gloves-businessman.jpg\",\"width\":1024,\"height\":683,\"mime_type\":\"image\\/jpeg\",\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg\"}},\"image_meta\":{\"aperture\":0,\"credit\":\"\",\"camera\":\"\",\"caption\":\"\",\"created_timestamp\":0,\"copyright\":\"\",\"focal_length\":0,\"iso\":0,\"shutter_speed\":0,\"title\":\"\",\"orientation\":0,\"keywords\":[]},\"filesize\":48859},\"source_url\":\"https:\\/\\/techcrunch.com\\/wp-content\\/uploads\\/2016\\/03\\/boxing-gloves-businessman.jpg\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/media\\/1287084\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/media\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/types\\/attachment\"}],\"replies\":[{\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/comments?post=1287084\"}],\"author\":[{\"embeddable\":true,\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/tc\\/v1\\/users\\/89646803\"}]}}],\"wp:term\":[[{\"id\":337,\"link\":\"https:\\/\\/techcrunch.com\\/health\\/\",\"name\":\"Health\",\"slug\":\"health\",\"taxonomy\":\"category\",\"parent\":0,\"rapidData\":{\"pt\":\"\",\"pct\":\"\"},\"submenu_categories\":[],\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories\\/337\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/category\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?categories=337\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?categories=337\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?categories=337\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":576601753,\"link\":\"https:\\/\\/techcrunch.com\\/lawsuit\\/\",\"name\":\"Lawsuit\",\"slug\":\"lawsuit\",\"taxonomy\":\"category\",\"parent\":0,\"rapidData\":{\"pt\":\"\",\"pct\":\"\"},\"submenu_categories\":[],\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories\\/576601753\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/category\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?categories=576601753\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?categories=576601753\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?categories=576601753\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":17396,\"link\":\"https:\\/\\/techcrunch.com\\/tc\\/\",\"name\":\"TC\",\"slug\":\"tc\",\"taxonomy\":\"category\",\"parent\":0,\"rapidData\":{\"pt\":\"\",\"pct\":\"\"},\"submenu_categories\":[],\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories\\/17396\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/categories\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/category\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?categories=17396\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?categories=17396\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?categories=17396\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}}],[{\"id\":576646100,\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/caredx\\/\",\"name\":\"CareDx\",\"slug\":\"caredx\",\"taxonomy\":\"post_tag\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\\/576646100\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/post_tag\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?tags=576646100\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/battlefield-companies?tags=576646100\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?tags=576646100\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?tags=576646100\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?tags=576646100\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":213276350,\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/guardant-health\\/\",\"name\":\"guardant health\",\"slug\":\"guardant-health\",\"taxonomy\":\"post_tag\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\\/213276350\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/post_tag\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?tags=213276350\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/battlefield-companies?tags=213276350\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?tags=213276350\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?tags=213276350\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?tags=213276350\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":2773040,\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/illumina\\/\",\"name\":\"Illumina\",\"slug\":\"illumina\",\"taxonomy\":\"post_tag\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\\/2773040\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/post_tag\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?tags=2773040\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/battlefield-companies?tags=2773040\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?tags=2773040\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?tags=2773040\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?tags=2773040\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":576646101,\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/natera\\/\",\"name\":\"Natera\",\"slug\":\"natera\",\"taxonomy\":\"post_tag\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\\/576646101\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/post_tag\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?tags=576646101\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/battlefield-companies?tags=576646101\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?tags=576646101\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?tags=576646101\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?tags=576646101\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":245607,\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/sequoia-capital\\/\",\"name\":\"sequoia capital\",\"slug\":\"sequoia-capital\",\"taxonomy\":\"post_tag\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\\/245607\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/post_tag\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?tags=245607\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/battlefield-companies?tags=245607\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?tags=245607\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?tags=245607\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?tags=245607\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}},{\"id\":602846,\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/stanford-university\\/\",\"name\":\"Stanford University\",\"slug\":\"stanford-university\",\"taxonomy\":\"post_tag\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\\/602846\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tags\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/post_tag\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?tags=602846\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/battlefield-companies?tags=602846\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc-media-gallery?tags=602846\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?tags=602846\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_video?tags=602846\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}}],[{\"id\":576646128,\"link\":\"https:\\/\\/techcrunch.com\\/?taxonomy=_tc_cb_tag_taxonomy&term=natera-organization\",\"name\":\"natera-organization\",\"slug\":\"natera-organization\",\"taxonomy\":\"_tc_cb_tag_taxonomy\",\"_links\":{\"self\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/crunchbase_tag\\/576646128\"}],\"collection\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/crunchbase_tag\"}],\"about\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/taxonomies\\/_tc_cb_tag_taxonomy\"}],\"wp:post_type\":[{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/posts?crunchbase_tag=576646128\"},{\"href\":\"https:\\/\\/techcrunch.com\\/wp-json\\/wp\\/v2\\/tc_topic?crunchbase_tag=576646128\"}],\"curies\":[{\"name\":\"wp\",\"href\":\"https:\\/\\/api.w.org\\/{rel}\",\"templated\":true}]}}],[],[]]}}],\"media\":[],\"events\":[],\"battlefieldEvents\":[],\"battlefieldCompanies\":[],\"battlefieldPages\":[]},\"current_posts\":[1801038],\"request\":\"\\/2019\\/03\\/26\\/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\\/\",\"siteURI\":\"https:\\/\\/techcrunch.com\\/\",\"totalPages\":\"0\",\"trending\":[{\"id\":\"60523764\",\"link\":\"https:\\/\\/techcrunch.com\\/fundings-exits\\/\",\"name\":\"Fundings & Exits\\n\",\"type\":\"category\"},{\"id\":\"576621827\",\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/cybersecurity-101\\/\",\"name\":\"Cybersecurity 101\\n\",\"type\":\"tag\"},{\"id\":\"449557111\",\"link\":\"https:\\/\\/techcrunch.com\\/asia\\/\",\"name\":\"\\nAsia\",\"type\":\"category\"},{\"id\":\"81\",\"link\":\"https:\\/\\/techcrunch.com\\/tag\\/google\\/\",\"name\":\"\\nGoogle\",\"type\":\"tag\"}],\"videoPlayerIds\":{\"no-ad-autostart\":\"56f58bbbe4b01497527036b2\",\"regular\":\"56df4e9de4b0c9c31d626c18\",\"regular-autostart\":\"56faf851e4b0d3dcac2e081a\",\"sideview-autostart\":\"57e2c53fcc52c7730882bbfe\"},\"facebookPixelId\":\"1447508128842484\",\"marketoAccountId\":\"270-WRY-762\",\"vidibleCompanyId\":\"564f313b67b6231408bc51ee\",\"recaptchaPublic\":\"6LeZyjwUAAAAABqkWH_Ct0efGn0B4pGU6ZLUeUvA\",\"googleAnalyticsID\":\"UA-991406-1\",\"googleAnalyticsDomains\":[\"techcrunch.com\"],\"googleMapsAPIKey\":\"AIzaSyCodzMYMBdZIpxThSQqm79ACyheeRXPPE4\",\"nps_survey_id\":\"386TPSJ\",\"nps_bucket_percentage\":\"0\",\"tinypass\":{\"scriptDomain\":\"https:\\/\\/dashboard.tinypass.com\",\"scriptURL\":\"https:\\/\\/cdn.tinypass.com\\/api\\/tinypass.min.js\",\"apiKey\":\"Fy7FpgyUxA\",\"apiURL\":\"https:\\/\\/api.tinypass.com\"},\"legacyPages\":{\"extra-crunch-membership\":1781464,\"sponsored\":1796357},\"apiNonce\":\"5ece0a23c2\",\"userCan\":{\"editPosts\":false,\"restNonce\":null},\"initialStore\":{\"events\":{\"eventTypeIDs\":[],\"eventPostIds\":[],\"featuredEventIDs\":{\"event_home\":[]},\"featuredPostIDs\":{},\"pastEventIDs\":{\"default\":[]},\"pastFilters\":{},\"pastLoading\":false,\"upcomingEventIDs\":{\"default\":null},\"upcomingFilters\":{},\"upcomingLoading\":false},\"section\":{\"allPosts\":[1801038],\"contentObject\":null,\"currentPage\":1,\"expandedPost\":\"https:\\/\\/techcrunch.com\\/2019\\/03\\/26\\/a-new-lawsuit-involving-stanford-and-sequoia-capital-highlights-fights-to-come-over-cell-free-dna-testing\\/\",\"expandedPostIds\":0,\"expandedIsland\":\"\",\"loading\":false,\"component\":\"singlePost\"}},\"extraCrunchMarketingPageURL\":\"\\/subscribe\",\"brandStudioMarketingPageURL\":\"\\/brand-studio\",\"unicornLeaderboardSlug\":\"unicorn-leaderboard\",\"newsletterURL\":\"http:\\/\\/link.techcrunch.com\\/join\\/134\\/signup-all-newsletters\"};\n/* ]]> */\n</script>\n<script src=\"https://techcrunch.com/_static/??/wp-content/themes/techcrunch-2017/build/ec/js/main.js,/wp-includes/js/wp-embed.min.js?m=1554501095j\" type=\"text/javascript\"></script>\n<script async=\"async\" defer=\"defer\" src=\"https://stats.wp.com/e-201914.js\" type=\"text/javascript\"></script>\n<script type=\"text/javascript\">\n\t_stq = window._stq || [];\n\t_stq.push([ 'view', {v:'ext',j:'1:7.2.1',blog:'136296444',post:'1801038',tz:'-7',srv:'techcrunch.com'} ]);\n\t_stq.push([ 'clickTrackerInit', '136296444', '1801038' ]);\n</script>\n<script type=\"text/javascript\">window.NREUM||(NREUM={});NREUM.info={\"beacon\":\"bam.nr-data.net\",\"licenseKey\":\"4750574831\",\"applicationID\":\"71001471\",\"transactionName\":\"NlRbNkYEWERTVkVcXA8eeAFADFlZHUZYW1QNVA==\",\"queueTime\":0,\"applicationTime\":252,\"atts\":\"GhNMQA4eSxsQVBMPSBxM\",\"errorBeacon\":\"bam.nr-data.net\",\"agent\":\"\"}</script></body>\n</html>\n"}